[Life-cycle assessment of single-use versus reusable surgical drapes (cellulose/polyethylene-mixed cotton system)].

M. Dettenkofer,R. Griesshammer,Martin Scherrer,F. Daschner

DOI: https://doi.org/10.1007/S001040050677

1999-04-01

Abstract:

What problem does this paper attempt to address?

Design, Synthesis and Biological Evaluation of 1-Phenanthryl-tetrahydroisoquinoline Derivatives As Novel P21-Activated Kinase 4 (PAK4) Inhibitors.

Shuai Song,Xiaodong Li,Jing Guo,Chenzhou Hao,Yan Feng,Bingyu Guo,Tongchao Liu,Qiaoling Zhang,Zhen Zhang,Ruijuan Li,Jian Wang,Bin Lin,Feng Li,Dongmei Zhao,Maosheng Cheng

DOI: https://doi.org/10.1039/c5ob00037h

2015-01-01

Organic & Biomolecular Chemistry

Abstract:Functional versatility and elevated expression in cancers have promoted p21-activated kinase 4 (PAK4) as one of the first-in-class anti-cancer drug targets. In this study, a series of novel 1-phenanthryl-tetrahydroisoquinoline analogues have been designed and synthesized as a novel class of small-molecule PAK4 inhibitors to fit into the cavity of PAK4. All of the target compounds were evaluated for their in vitro PAK4 inhibitory activities and antiproliferative activities. Lead optimization identified all the derivatives with more potency than the lead compound, especially compound 21a. Moreover, compound 21a significantly induced the cell cycle in the G1/S phase, and inhibited migration and invasion of MCF-7 cells via the regulation of the PAK4-LIMK1-cofilin signaling pathway. A molecular modeling study showed possible novel binding modes between 21a and PAK4 and provided a structural basis for further structure-guided design of PAK4 inhibitors.
Structure-Based Design of 6-Chloro-4-aminoquinazoline-2-carboxamide Derivatives As Potent and Selective P21-Activated Kinase 4 (PAK4) Inhibitors

Chenzhou Hao,Fan Zhao,Hongyan Song,Jing Guo,Xiaodong Li,Xiaolin Jiang,Ran Huan,Shuai Song,Qiaoling Zhang,Ruifeng Wang,Kai Wang,Yu Pang,Tongchao Liu,Tianqi Lu,Wanxu Huang,Jian Wang,Bin Lin,Zhonggui He,Haitao Li,Feng Li,Dongmei Zhao,Maosheng Cheng

DOI: https://doi.org/10.1021/acs.jmedchem.7b01342

IF: 8.039

2017-01-01

Journal of Medicinal Chemistry

Abstract:Herein, we report the discovery and characterization of a novel class of PAK4 inhibitors with a quinazoline scaffold. Based on the shape and chemical composition of the ATP-binding pocket of PAKs, we chose a 2,4-diaminoquinazoline series of inhibitors as a starting point. Guided by X-ray crystallography and a structure-based drug design (SBDD) approach, a series of novel 4-aminoquinazoline-2-carboxamide PAK4 inhibitors were designed and synthesized. The inhibitors' selectivity, therapeutic potency, and pharmaceutical properties were optimized. One of the best compounds, 31 (CZh226), showed remarkable PAK4 selectivity (346-fold vs PAK1) and favorable kinase selectivity profile. Moreover, this compound potently inhibited the migration and invasion of A549 tumor cells by regulating the PAK4-directed downstream signaling pathways in vitro. Taken together, these data support the further development of 31 as a lead compound for PAK4-targeted anticancer drug discovery and as a valuable research probe for the further biological investigation of group II PAKs.
Advances in the 1-Phenanthryl-tetrahydroisoquinoline Series of PAK4 Inhibitors: Potent Agents Restrain Tumor Cell Growth and Invasion

Chenzhou Hao,Xiaodong Li,Shuai Song,Bingyu Guo,Jing Guo,Jian Zhang,Qiaoling Zhang,Wanxu Huang,Jian Wang,Bin Lin,Maosheng Cheng,Feng Li,Dongmei Zhao

DOI: https://doi.org/10.1039/c6ob01072e

2016-01-01

Organic & Biomolecular Chemistry

Abstract:Discovery of a new class of natural product-inspired PAK4 inhibitors as potent anti-cancer agents.
Synthesis and biological evaluation of 7H-pyrrolo [2,3-d] pyrimidine derivatives as potential p21-activated kinase 4 (PAK4) inhibitors

Cong Wang,Jiawei Xia,Yan Lei,Rui Lu,Mingliang Zhang,He Lv,Qianqian Hong,Tao Lu,Yadong Chen,Hongmei Li

DOI: https://doi.org/10.1016/j.bmc.2022.116700

2022-04-01

Abstract:PAK4 has been validated as a crucial effector of various signal pathways and play an important role in driving tumor progression. Here, we developed a series of 7H-pyrrolo [2,3-d] pyrimidine derivatives as PAK4 inhibitors. Compounds 5n and 5o showed higher enzymatic inhibitory activities (IC50 = 2.7 and 20.2 nM, respectively) and potent activity (IC50 = 7.8 and 38.3 nM, respectively) against MV4-11 cell line. Further flow cytometry assay revealed that the compound 5n can arrest MV4-11 cells at G0/G1 phase and induce cell apoptosis. Molecular mechanism study indicated that compound 5n regulated the phosphorylation of PAK4 in vitro The docking study supported that compound 5n binds to PAK4 through various hydrogen bonding interactions and hydrophobic interactions. Thus, compound 5n represents a promising lead for the discovery of PAK4 directed therapeutic agents and may be considered for further drug development.

biochemistry & molecular biology,chemistry, medicinal, organic
Design, synthesis and anticancer activity evaluation of 4-(3-1f H -indazolyl)amino quinazoline derivatives as PAK4 inhibitors

Wei Han,Yusang Yang,Fan Yu,Qianqian Li,Anyao Liu,Wenbo Xu,Jiabin Li,Xiaowen Xue

DOI: https://doi.org/10.1016/j.bmc.2023.117501

IF: 3.461

2023-10-15

Bioorganic & Medicinal Chemistry

Abstract:A novel series of 4-(3-1 H -indazolyl)amino quinazoline derivatives were developed as PAK4 inhibitors based on a scaffold hopping strategy. Compounds 27e , 27g , 27i and 27j were found to exhibit potent inhibitory activity against PAK4 (IC 50 = 10, 13, 11 and 9 nM, respectively). Subsequent cellular assay demonstrated that compound 27e possessed the strongest antiproliferative activity against A549 cells with an IC 50 value of 0.61 μM, a little bit better than PF-3758309. Further anticancer mechanistic investigation revealed that compound 27e significantly induced apoptosis of A549 cells in a concentration-dependent manner and blocked the cell cycle at phase G0/G1. A docking model between compound 27e and PAK4 was proposed to elucidate its possible binding modes. As a promising PAK4 inhibitor, compound 27e may serve as a candidate for the development of novel PAK4-targeted anticancer drug.

biochemistry & molecular biology,chemistry, medicinal, organic
Design, synthesis and biological evaluation of novel tetrahydrothieno [2,3-c]pyridine substitued benzoyl thiourea derivatives as PAK1 inhibitors in triple negative breast cancer

Dahong Yao,Jian Huang,Jinhui Wang,Zhendan He,Jin Zhang

DOI: https://doi.org/10.1080/14756366.2020.1797710

2020-01-01

Journal of Enzyme Inhibition and Medicinal Chemistry

Abstract:The overexpression of P21-activated kinase 1 (PAK1) is associated with poor prognosis in several cancers, which has emerged as a promising drug targets. Based on high-throughput virtual screening strategy, tetrahydrothieno [2,3-c]pyridine scaffold was identified as an initial lead for targeting PAK1. Herein we reported our structure-based optimisation strategy to discover a potent PAK1 inhibitor (7j) which displayed potent PAK1 inhibition and antiproliferatory activity in MDA-MB-231 cells. 7j induced obviously G2/M cell cycle arrest via PAK1-cdc25c-cdc2 pathway, and also inhibited MAPK-ERK and MAPK-JNK cascade to induce MDA-MB-231 cell death. Together, these results provided a novel chemical scaffold as PAK1 inhibitor for breast cancer treatment.

biochemistry & molecular biology,chemistry, medicinal
Synthesis of Selective PAK4 Inhibitors for Lung Metastasis of Lung Cancer and Melanoma Cells

Peilu Song,Fan Zhao,Dahong Li,Jiqiang Qu,Miao Yao,Yuan Su,Hanxun Wang,Miaomiao Zhou,Yujie Wang,Yinli Gao,Feng Li,Dongmei Zhao,Fengjiao Zhang,Yu Rao,Mingyu Xia,Haitao Li,Jian Wang,Maosheng Cheng

DOI: https://doi.org/10.1016/j.apsb.2022.02.029

IF: 14.903

2022-01-01

Acta Pharmaceutica Sinica B

Abstract:The p21 activated kinase 4 (PAK4) is serine/threonine protein kinase that is critical for cancer progression. Guided by X-ray crystallography and structure-based optimization, we report a novel subseries of C-3-substituted 6-ethynyl-1H-indole derivatives that display high potential and specificity towards group II PAKs. Among these inhibitors, compound 55 exhibited excellent inhibitory activity and kinase selectivity, displayed superior anti-migratory and anti-invasive properties against the lung cancer cell line A549 and the melanoma cell line B16. Compound 55 exhibited potent in vivo antitumor metastatic efficacy, with over 80% and 90% inhibition of lung metastasis in A549 or B16-BL6 lung metastasis models, respectively. Further mechanistic studies demonstrated that compound 55 mitigated TGF-β1-induced epithelial-mesenchymal transition (EMT).
Design, Synthesis, and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives As Novel PI3K/mTOR Dual Inhibitors.

Ya'nan Yu,Yuqiao Han,Fupo Zhang,Zhenmei Gao,Tong Zhu,Suzhen Dong,Mingliang Ma

DOI: https://doi.org/10.1021/acs.jmedchem.9b01736

IF: 8.039

2020-01-01

Journal of Medicinal Chemistry

Abstract:PI3K-Akt-mTOR signaling pathway has been validated as an effective targeting pathway for cancer therapy. However, no PI3K/mTOR dual inhibitor has been approved by the FDA yet. Therefore, it is still essential to discover a candidate with good efficacy and low toxicity. In our design, a series of imidazo[1,2-a]pyridine derivatives had been synthesized and subjected to activity assessment in vitro and in vivo. 15a was proved to be a potent PI3K/mTOR dual inhibitor with excellent kinase selectivity, modest plasma clearance, and acceptable oral bioavailability. Besides, 15a displayed significant inhibition of tumor growth in HCT116 and HT-29 xenografts without obvious effect on body weight.
Design, Synthesis, and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors

Ya'nan Yu,Yuqiao Han,Fupo Zhang,Zhenmei Gao,Tong Zhu,Suzhen Dong,Mingliang Ma

DOI: https://doi.org/10.1021/acs.jmedchem.9b01736

IF: 8.039

2020-01-01

Journal of Medicinal Chemistry

Abstract:PI3K-Akt-mTOR signaling pathway has been validated as an effective targeting pathway for cancer therapy. However, no PI3K/mTOR dual inhibitor has been approved by the FDA yet. Therefore, it is still essential to discover a candidate with good efficacy and low toxicity. In our design, a series of imidazo[1,2-a]pyridine derivatives had been synthesized and subjected to activity assessment in vitro and in vivo. 15a was proved to be a potent PI3K/mTOR dual inhibitor with excellent kinase selectivity, modest plasma clearance, and acceptable oral bioavailability. Besides, 15a displayed significant inhibition of tumor growth in HCT116 and HT-29 xenografts without obvious effect on body weight.
Design, Synthesis, Structure-Activity Relationships Study and X-ray Crystallography of 3-Substituted-indolin-2-one-5-carboxamide Derivatives As PAK4 Inhibitors.

Jing Guo,Fan Zhao,Wenbo Yin,Mingyue Zhu,Chenzhou Hao,Yu Pang,Tianxiao Wu,Jian Wang,Dongmei Zhao,Haitao Li,Maosheng Cheng

DOI: https://doi.org/10.1016/j.ejmech.2018.05.051

IF: 7.088

2018-01-01

European Journal of Medicinal Chemistry

Abstract:We have previously described the identification of indolin-2-one-5-carboxamides as potent PAK4 inhibitors. This study expands the structure-activity relationships on our original series by presenting several modifications in the lead compounds, 2 and 3. A series of novel derivatives was designed, synthesized, and evaluated in biochemical and cellular assay. Most of this series displayed nanomolar biochemical activity and potent antiproliferative activity against A549 and HCT116 cells. The representative compound 10a exhibited excellent enzyme inhibition (PAK4 IC50 = 25 nM) and cellular potency (A549 IC50 = 0.58 μM, HCT116 IC50 = 0.095 μM). An X-ray structure of compound 10a bound to PAK4 was obtained. Crystallographic analysis confirmed predictions from molecular modeling and helped refine SAR results. In addition, Compound 10a displayed focused multi-targeted kinase inhibition, good calculated drug-likeness properties. Further profiling of compound 10a revealed it showed weak inhibitory activity against various isoforms of human cytochrome P450.
Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors

Yiyu Gu,Xiaoqing Lu,Xiaodong Ma,Haojian Zhang,Yuanyuan Ji,Wanjing Ding,Li Shen

DOI: https://doi.org/10.6023/cjoc201908021

2020-01-01

Abstract:Polypharmacology has emerged as a promising approach to drug discovery, especially antitumor drug. This study reports the design, synthesis, and biological evaluation of novel phosphatidylinositol 3-kinases (PI3Ks) and histone deacetylases (HDACs) dual inhibitors on the basis of GSK2126458 under clinical evaluation and vorinostat approved. Among these hybrid molecules, GYB-4 and GYB-5 possessed potent inhibition against both PI3K alpha (1.0 and 1.3 nmol/L, respectively) and HDAC1 (4.2 and 4.8 nmol/L, respectively). Antiproliferative assays with HCT116, PC3 and A2780 cell lines subsequently were performed. The structure-activity relationship study will guide to optimization of dual PI3K and HDAC inhibitors.
Recent advances on development of p21-activated kinase 4 inhibitors as anti-tumor agents

Yang Li,Qing Lu,Chenghu Xie,Yiming Yu,Ao Zhang

DOI: https://doi.org/10.3389/fphar.2022.956220

2022-08-29

Abstract:The p21-activated kinase 4 (PAK4) is a member of the PAKs family. It is overexpressed in multiple tumor tissues. Pharmacological inhibition of PAK4 attenuates proliferation, migration, and invasion of cancer cells. Recent studies revealed that inhibition of PAK4 sensitizes immunotherapy which has been extensively exploited as a new strategy to treat cancer. In the past few years, a large number of PAK4 inhibitors have been reported. Of note, the allosteric inhibitor KPT-9274 has been tested in phase Ⅰ clinic trials. Herein, we provide an update on recent research progress on the PAK4 mediated signaling pathway and highlight the development of the PAK4 small molecular inhibitors in recent 5 years. Meanwhile, challenges, limitations, and future developmental directions will be discussed as well.
Design and synthesis of 1H-indazole-3-carboxamide derivatives as potent and selective PAK1 inhibitors with anti-tumour migration and invasion activities

Mingliang Zhang,Xiaobao Fang,Cong Wang,Yi Hua,Chen Huang,Meng Wang,Lu Zhu,Zixu Wang,Yuhan Gao,Tianyi Zhang,Haichun Liu,Yanmin Zhang,Shuai Lu,Tao Lu,Yadong Chen,Hongmei Li

DOI: https://doi.org/10.1016/j.ejmech.2020.112517

IF: 7.088

2020-10-01

European Journal of Medicinal Chemistry

Abstract:Aberrant activation of p21-activated kinase 1 (PAK1) is associated with tumour progression, and PAK1 has been recognized as a promising target for anticancer drug discovery. However, the development of potent PAK1 inhibitors with satisfactory kinase selectivity and favourable physicochemical properties remains a daunting challenge. Herein, we identified the 1H-indazole-3-carboxamide derivatives as potential PAK1 inhibitors using a fragment-based screening approach. The representative compound 30l exhibited excellent enzyme inhibition (PAK1 IC50 = 9.8 nM) and high PAK1 selectivity toward a panel of 29 kinases. The Structure-activity relationship (SAR) analysis showed that substituting of an appropriate hydrophobic ring in the deep back pocket and introducing a hydrophilic group in the bulk solvent region were critical for PAK1 inhibitory activity and selectivity. Additionally, the hERG channel activity of 30l demonstrated its low risk of hERG toxicity. Furthermore, it significantly suppressed the migration and invasion of MDA-MB-231 cells by downregulating Snail expression without affecting the tumour growth. These results provide a new type of chemical scaffolds targeting PAK1 and suggested that 1H-indazole-3-carboxamide derivatives may serve as lead compounds for the development of potential and selective PAK1 inhibitors.

chemistry, medicinal
Perinatal Generalized Anxiety Disorder: Assessment and Treatment.

S. Misri,Jasmin Abizadeh,Shawn W. Sanders,Elena Swift

DOI: https://doi.org/10.1089/jwh.2014.5150

2015-09-21

Abstract:Perinatal generalized anxiety disorder (GAD) has a high prevalence of 8.5%-10.5% during pregnancy and 4.4%-10.8% postpartum. Despite its attendant dysfunction in the patient, this potentially debilitating mental health condition is often underdiagnosed. This overview will provide guidance for clinicians in making timely diagnosis and managing symptoms appropriately. A significant barrier to the diagnosis of GAD in the perinatal population is difficulty in distinguishing normal versus pathological worry. Because a perinatal-specific screening tool for GAD is nonexistent, early identification, diagnosis and treatment is often compromised. The resultant maternal dysfunction can potentially impact mother-infant bonding and influence neurodevelopmental outcomes in the children. Comorbid occurrence of GAD and major depressive disorder changes the illness course and its treatment outcome. Psychoeducation is a key component in overcoming denial/stigma and facilitating successful intervention. Treatment strategies are contingent upon illness severity. Cognitive behavior therapy (CBT), relaxation, and mindfulness therapy are indicated for mild GAD. Moderate/severe illness requires pharmacotherapy and CBT, individually or in combination. No psychotropic medications are approved by the FDA or Health Canada in pregnancy or the postpartum; off-label pharmacological treatment is instituted only if the benefit of therapy outweighs its risk. SSRIs/SNRIs are the first-line treatment for anxiety disorders due to data supporting their efficacy and overall favorable side effect profile. Benzodiazepines are an option for short-term treatment. While research on atypical antipsychotics is evolving, some can be considered for severe manifestations where the response to antidepressants or benzodiazepines has been insufficient. A case example will illustrate the onset, clinical course, and treatment strategies of GAD through pregnancy and the postpartum.
Design, Synthesis, Biological Evaluation, and Molecular Docking of Novel Benzopyran and Phenylpyrazole Derivatives as Akt Inhibitors.

Wenhu Zhan,Sendong Lin,Jing Chen,Xiaowu Dong,Jianbo Chu,Wenting Du

DOI: https://doi.org/10.1111/cbdd.12489

2015-01-01

Chemical Biology & Drug Design

Abstract:By inspiration of good Akt1 inhibitory and cytotoxic activity of our previously screened hits 1 and 2, a series of novel benzopyrans 3a-c, 4 and phenylpyrazoles 5a-c, 6a-b, and 7 were designed, synthesized, and biologically evaluated for their in vitro Akt1 inhibitory and cytotoxic activity. The results revealed that all of these compounds showed moderate-to-excellent antiproliferative effects against the tested cancer cell lines (i.e. HL-60, OVCAR, PC-3, and HepG2). Among them, compounds 3a and 3c exhibited preferable Akt1 inhibitory activities (IC50 of 3a and 3c are 6.18 and 5.28m, respectively), while compounds 4, 5a-c, 6a-b, and 7 only showed weak Akt1 inhibitory activities. Consequently, we used molecular docking and dynamic simulation to propose a mode of binding between Akt1 and the 3c compound.
Synthesis, biological evaluation, and molecular docking studies of N,1,3-triphenyl-1H-pyrazole-4-carboxamide derivatives as anticancer agents.

Xi Li,Xiang Lu,Man Xing,Xian-Hui Yang,Ting-Ting Zhao,Hai-Bin Gong,Hai-Liang Zhu

DOI: https://doi.org/10.1016/j.bmcl.2012.04.066

IF: 2.94

2012-01-01

Bioorganic & Medicinal Chemistry Letters

Abstract:A series of N,1,3-triphenyl-1H-pyrazole-4-carboxamide derivatives have been designed, synthesized and evaluated for their potential antiproliferation activity against Aurora-A kinase. Among all the compounds, compound 10e possessed the most potent biological activity against HCT116 with IC50 values of 0.39±0.06μM, which was comparable to the positive control. The results of Docking simulation and Western-blot assay futher demonstrated that compound 10e possessed good Aurora-A kinase inhibitory activity against HCT116. Based on the preliminary results, it is deduced that compound 10e with potent Aurora-A kinase inhibitory activity may be a potential anticancer agent.
Development of Novel Chromeno[4,3-C]pyrazol-4(2h)-one Derivates Bearing Sulfonylpiperazine As Antitumor Inhibitors Targeting PI3Kα.

Yong Yin,Shao Sha,Xun Wu,She-Feng Wang,Fang Qiao,Zhong-Cheng Song,Hai-Liang Zhu

DOI: https://doi.org/10.1016/j.ejmech.2019.111630

IF: 7.088

2019-01-01

European Journal of Medicinal Chemistry

Abstract:A series of novel chromeno[4,3-c]pyrazol-4(2H)-one derivates contained sulfonamido were designed and synthesized, and their anticancer effects in vitro was evaluated to develop some new PI3Kα inhibitors. Most of desired compounds exhibited the better antiproliferative activities against four cancer cell lines than that of LY294002. Out of them, compound 4o displayed the potent antiproliferative activity and high selectivity against the PI3Kα protein and it can induce apoptosis of HCT116 in a dose-dependent manner. Western blot assay indicated that compound 4o obviously down-regulated expression of p-Akt (S473). Molecular docking was performed to clarify the possible binding mode between compound 4o and PI3Kα. All these results indicated that compound 4o could be a potential inhibitor of PI3Kα.
Precise design of highly isoform-selective p21-activated kinase 4 inhibitors: computational insights into the selectivity mechanism through molecular dynamics simulation and binding free energy calculation

Yuan Su,Peilu Song,Hanxun Wang,Baichun Hu,Jian Wang,Mao-Sheng Cheng

DOI: https://doi.org/10.1080/07391102.2019.1664330

2019-09-15

Journal of Biomolecular Structure and Dynamics

Abstract:Understanding the selectivity mechanisms of inhibitors towards highly similar protein kinases is the first step in discovering new selective candidate for satisfactory safety profile. P21-activated kinases (PAKs) are pertain to a family of serine/threonine (Ser/Thr) protein kinases, which are the first Rho family GTPase-regulated kinases identified and served as important downstream mediators of Ras-Rac and Cdc42 function. Among PAKs, PAK4 is emerging as a promising target for cancer treatment. Since the PAK2 inhibition correlates with increased acute cardiovascular toxicity, which may be enhanced by PAK1 inhibitor, selective inhibition of PAK4 over PAK1 is crucial in discovering safe anticancer candidates with optimal therapeutic efficacy. While the conserved ATP-binding pockets of both PAK1/4 make it challenging to discriminating selective inhibitors between PAK1 and PAK4, thus the selectivity mechanism of PAK1/4 inhibitors will be explored in this present study through, computational strategies which combine molecular docking, structural comparison, molecular dynamics simulation and molecular mechanics/generalized Born surface area calculation. The research would provide valuable insight into the selectivity mechanism of PAK4 inhibitors over PAK1 and thus be helpful for designing selective PAK4 inhibitors.Communicated by Ramaswamy H. Sarma

English Else
Design, Synthesis and Biological Evaluation of Novel 4-Alkynyl-quinoline Derivatives As PI3K/mTOR Dual Inhibitors.

Xiaoqing Lv,Huazhou Ying,Xiaodong Ma,Ni Qiu,Peng Wu,Bo Yang,Yongzhou Hu

DOI: https://doi.org/10.1016/j.ejmech.2015.05.025

IF: 7.088

2015-01-01

European Journal of Medicinal Chemistry

Abstract:A novel series of 4-alkynyl-quinoline derivatives were designed, synthesized and biologically evaluated for their PI3Kα inhibitory activities and anti-proliferative effects against two cancer cell lines PC-3 and HCT-116. Most of them showed potent PI3Kα inhibitory activities with IC50 values at low nanomolar level and good to excellent anti-proliferative effects against both cell lines. Among them, compound 15d, the most potent one, was selected for further biological evaluation. As a result, 15d displayed strong inhibitory activity against other class I PI3K isoforms (PI3Kβ, PI3Kγ and PI3Kδ) and mTOR with an acceptable kinase selectivity profile. Moreover, the western blot assay indicated that the phosphorylation of Akt, another downstream effector of PI3K, can be remarkably suppressed by 15d at cellular level. All these experimental results suggested that 15d is a potent PI3K/mTOR dual inhibitor and could serve as a promising lead compound for the development of anticancer agents.
Structure-based drug design, synthesis, and biological evaluation of novel 1,3,5-triazine or pyrimidine derivatives containing benzoyl hydrazine moiety as PI3Kα selective inhibitors

Siyu Fu,Jiuyu Liu,Chunting Li,Jiakuan Wei,Hao Yue,Ao Yang,Kang Wang,Yongshuo Wu,Yunlei Hou,Yanfang Zhao

DOI: https://doi.org/10.1016/j.bioorg.2023.106738

IF: 5.307

2023-07-01

Bioorganic Chemistry

Abstract:Phosphoinositide 3-kinase (PI3K) was an important cellular signal transducer, while PI3Kα was the most mutated family member in cancer. Selective PI3Kα inhibitors have become the frequent research in recent years because of their excellent curative effect and reduced side effects. Here, we described a series of PI3Kα inhibitors with 1,3,5-triazine or pyrimidine skeleton containing benzoyl hydrazine based on the pan-PI3K inhibitor ZSTK474 relying on the strategies of structure-based drug discovery (SBDD) and computer-aided drug design (CADD). Among them, compound F8 exhibited improved selective PI3Kα inhibition with an IC50 value of 0.14 nM and more significant anti-proliferative activities against three tumor-derived cell lines (PC-3 IC50 = 0.28 μM, HCT-116 IC50 = 0.57 μM, and U87-MG IC50 = 1.37 μM) than ZSTK-474. Compound F-8 induced a great decrease in mitochondrial membrane which caused cell cycle arrest at G1 phase and apoptosis in U87-MG cells in a dose-dependent manner. Furthermore, compound F8 induced significant tumor regressions in a xenograft mouse model of U87-MG cell line with no clear evidence of toxicity following intraperitoneal injection of 40 mg/kg. Compound F8 may serve as a PI3Kα-selective inhibitor and provided the opportunity to spare patients the side effects associated with broader inhibition of the class I PI3K family.

biochemistry & molecular biology,chemistry, organic

[Life-cycle assessment of single-use versus reusable surgical drapes (cellulose/polyethylene-mixed cotton system)].

Design, Synthesis and Biological Evaluation of 1-Phenanthryl-tetrahydroisoquinoline Derivatives As Novel P21-Activated Kinase 4 (PAK4) Inhibitors.

Structure-Based Design of 6-Chloro-4-aminoquinazoline-2-carboxamide Derivatives As Potent and Selective P21-Activated Kinase 4 (PAK4) Inhibitors

Advances in the 1-Phenanthryl-tetrahydroisoquinoline Series of PAK4 Inhibitors: Potent Agents Restrain Tumor Cell Growth and Invasion

Synthesis and biological evaluation of 7H-pyrrolo [2,3-d] pyrimidine derivatives as potential p21-activated kinase 4 (PAK4) inhibitors

Design, synthesis and anticancer activity evaluation of 4-(3-1f H -indazolyl)amino quinazoline derivatives as PAK4 inhibitors

Design, synthesis and biological evaluation of novel tetrahydrothieno [2,3-c]pyridine substitued benzoyl thiourea derivatives as PAK1 inhibitors in triple negative breast cancer

Synthesis of Selective PAK4 Inhibitors for Lung Metastasis of Lung Cancer and Melanoma Cells

Design, Synthesis, and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives As Novel PI3K/mTOR Dual Inhibitors.

Design, Synthesis, and Biological Evaluation of Imidazo[1,2-<i>a</i>]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors

Design, Synthesis, Structure-Activity Relationships Study and X-ray Crystallography of 3-Substituted-indolin-2-one-5-carboxamide Derivatives As PAK4 Inhibitors.

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors

Recent advances on development of p21-activated kinase 4 inhibitors as anti-tumor agents

Design and synthesis of 1H-indazole-3-carboxamide derivatives as potent and selective PAK1 inhibitors with anti-tumour migration and invasion activities

Perinatal Generalized Anxiety Disorder: Assessment and Treatment.

Design, Synthesis, Biological Evaluation, and Molecular Docking of Novel Benzopyran and Phenylpyrazole Derivatives as Akt Inhibitors.

Synthesis, biological evaluation, and molecular docking studies of N,1,3-triphenyl-1H-pyrazole-4-carboxamide derivatives as anticancer agents.

Development of Novel Chromeno[4,3-C]pyrazol-4(2h)-one Derivates Bearing Sulfonylpiperazine As Antitumor Inhibitors Targeting PI3Kα.

Precise design of highly isoform-selective p21-activated kinase 4 inhibitors: computational insights into the selectivity mechanism through molecular dynamics simulation and binding free energy calculation

Design, Synthesis and Biological Evaluation of Novel 4-Alkynyl-quinoline Derivatives As PI3K/mTOR Dual Inhibitors.

Structure-based drug design, synthesis, and biological evaluation of novel 1,3,5-triazine or pyrimidine derivatives containing benzoyl hydrazine moiety as PI3Kα selective inhibitors